Skip to content
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

NEW MOLECULE TAKES THE HIGH OUT OF METH AND COCAINE

by Bennett Daviss
Scientists led by a Duke University research team have created a new molecule that weakens the high that cocaine and methamphetamines deliver to the brain.
The molecule is a neurotensin, a kind of protein that moderates reward-seeking behaviors and has been known to reduce food- and drug-seeking in mice.
Using a neurotensin to curb drug addiction isn’t a new idea. But previous attempts have resulted in concoctions that slow blood pressure and drop body temperatures to dangerous levels and also impair physical coordination.
The new molecule, known as SBI-553, causes fewer and less severe side effects.
In tests, mice were treated with SBI-553 and then allowed to ingest either cocaine or  methamphetamine. The new molecule calmed the usual hyperactivity that results from drug use and dulled the brain’s pleasure centers that the narcotics activate.
After 20 minutes to an hour, the treated mice were given access to more coke and meth but voluntarily reduced their intake by about 80 percent and showed none of neurotensins’ usual side effects.
TRENDPOST: This new therapeutic molecule moves the issue of drug addiction closer to being understood and treated as a manageable, or even curable, condition instead of as a moral failing or a crime.

Comments are closed.